CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 188 enrolled
Drug / intervention
niacin (+) laropiprant (Source 1) +1 moredrug
Likely dose
niacin (+) laropiprant (Source 1) 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00944645
NCT00944645Phase 1Completed
CompareCT.gov

An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets

Merck Sharp & Dohme LLC·interventional·Posted Jul 23, 2009·Updated Jun 19, 2015

In Brief

A Phase 1 clinical trial evaluating niacin (+) laropiprant (Source 1) and Comparator: niacin (+) laropiprant (Source 2) for Dyslipidemia. Completed, enrolled 188 participants.

Detailed Summary

This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 23, 2009
Enrollment StartOct 1, 2006
Primary CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.9 years ago

Interventions

niacin (+) laropiprant (Source 1)drug

Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.

Comparator: niacin (+) laropiprant (Source 2)drug

Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.